Establishment of a predictive model of death within 30 days for patients with liver cirrhosis and bacterial ascites

Huang YunYi; Wang XianBo

doi:10.3969/j.issn.1001-5256.2019.11.017

Volume 35 Issue 11

Nov. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(11): 2472-2477

PDF( 2346 KB)

Establishment of a predictive model of death within 30 days for patients with liver cirrhosis and bacterial ascites

DOI: 10.3969/j.issn.1001-5256.2019.11.017

Dongzhimen Hospital,Beijing University of Chinese Medicine

Research funding:

Received Date: 2019-07-02
Published Date: 2019-11-20

Abstract

Abstract

Objective To investigate the risk factors for death within 30 days in patients with liver cirrhosis and bacterial ascites,and to establish a predictive model of death within 30 days. Methods A retrospective analysis was performed for the clinical data of 86 patients with liver cirrhosis and bacterial ascites who were admitted to Beijing Ditan Hospital,Capital Medical University,from January 2012 to April 2018.The patients were followed up for 30 days,and according to their prognosis,they were divided into survival group with 73 patients and death group with 13 patients. The t-test was used for comparison of normally distributed continuous data between groups,and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. A logistic regression analysis was used to investigate the influencing factors for death within 30 days in patients with liver cirrhosis and bacterial ascites,and a predictive model was established based on these influencing factors. The area under the receiver operating characteristic curve was used to evaluate the predictive value of each independent influencing factor and the predictive model. Results The multivariate logistic regression analysis showed that there were significant differences between the survival group and the death group in ascites albumin( odds ratio [OR]= 0. 615,95% confidence interval [CI]: 0. 424-0. 893,P = 0. 011),neutrophil-to-lymphocyte ratio( NLR)( OR =1. 170,95% CI: 1. 011-1. 354,P = 0. 035),and Model for End-Stage Liver Disease( MELD) score( OR = 1. 341,95%CI: 1. 111-1. 618,P = 0. 002). A scoring model was established based on the results of the multivariate analysis to predict death within 30 days in patients with liver cirrhosis and bacterial ascites,and based on this model,the patients were divided into high-risk group with death within 30 days( score ≥2 points) and low-risk group with death within 30 days( score < 2 points). There was a significant difference in mortality rate with 30 days between the two groups( 60. 0% vs 5. 6%,P < 0. 001). Conclusion Ascites albumin ≤3. 5 g/L,NLR ≥6. 5,and MELD score ≥20 are independent risk factors for death within 30 days in patients with liver cirrhosis and bacterial ascites. The predictive model established on this basis can effectively evaluate the population at high risk of death within 30 days.
- liver cirrhosis,
- bacterial ascites,
- peritonitis,
- prognosis,
- logistic models

FullText(HTML)

References(21)

References

[1] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J]. J Hepatol,2010,53(3):397-417.

[2] TANDON P,KUMAR D,SEO YS,et al. The 22/11 risk prediction model:A validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Am J Gastroenterol,2013,108(9):1473-1479.

[3] ANGELONI S,LEBOFFE C,PARENTE A,et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice[J]. World J Gastroenterol,2008,14(17):2757-2762.

[4] RUNYON BA,AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis:An update[J]. Hepatology,2009,49(6):2087-2107.

[5] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol,2017,33(10):1847-1863.(in Chinese)中华医学会肝病学分会．肝硬化腹水及相关并发症的诊疗指南[J]．临床肝胆病杂志，2017,33(10):1847-1863.

[6] CHEN HZ. Practical internal medicine[M]. Beijing:People’s Medical Publishing House,2001:1850.(in Chinese)陈灏珠．实用内科学[M]．北京:人民卫生出版社，2001:1850.

[7] ILIAZ R,OZPOLAT T,BARAN B,et al. Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers[J]. Eur J Gastroenterol Hepatol,2018,30(7):786-791.

[8] OLIVEIRA AM,BRANCO JC,BAROSA R,et al. Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis:A multicenter cohort study[J]. Eur J Gastroenterol Hepatol,2016,28(10):1216-1222.

[9] HEO J,SEO YS,YIM HJ,et al. Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis:A multicenter retrospective study[J]. Gut Liver,2009,3(3):197-204.

[10] NOBRE SR,CABRAL JE,GOMES JJ,et al. In-hospital mortality in spontaneous bacterial peritonitis:A new predictive model[J]. Eur J Gastroenterol Hepatol,2008,20(12):1176-1181.

[11] XIONG Q,ZHOU YF,YANG GW. Changes and significance of serum and ascites CA125 and albumin levels in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Shandong Med J,2016,56(13):43-44.(in Chinese)熊琴，周英发，杨国威．肝硬化并自发性细菌性腹膜炎患者血清和腹水中CA125、白蛋白水平变化及意义[J]．山东医药，2016,56(13):43-44.

[12] FERNANDEZ J,NAVASA M,GARCIA-PAGAN JC,et al.Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis[J]. J Hepatol,2004,41(3):384-390.

[13] FAN Y,LI X,ZHOU XF,et al. Value of neutrophil-lymphocyte ratio in predicting hepatitis B-related liver failure[J]. Chin J Hepatol,2017,25(10):726-731.(in Chinese)范玥，李欣，周晓芳，等．中性粒细胞淋巴细胞比值在预测乙型肝炎相关肝衰竭中的作用[J]．中华肝脏病杂志，2017,25(10):726-731.

[14] FERNANDEZ-RUIZ M,LOPEZ-MEDRANO F,ROMO EM,et al. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation[J].Liver Transpl,2009,15(10):1209-1216.

[15] GUARNER C,SORIANO G. Bacterial translocation and its consequences in patients with cirrhosis[J]. Eur J Gastroenterol Hepatol,2005,17(1):27-31.

[16] LI LJ,WU ZW. Study on the role of intestinal microecological changes in chronic liver diseases[J]. Chin J Microecol,2002,14(2):2-3.(in Chinese)李兰娟，吴仲文．重视肠道微生态变化在慢性肝病中作用的研究[J]．中国微生态学杂志，2002,14(2):2-3.

[17] GUO YN,XU YQ,WANG L. Study on the relationship between procalcitonin in ascites,cytokines and intestinal mucosal barrier function in patients with cirrhosis and spontaneous peritonitis[J]. J Clin Exp Med,2019,18(14):1528-1531.(in Chinese)郭玉宁，徐有青，王麟．肝硬化合并自发性细菌性腹膜炎患者腹水降钙素原与细胞因子和肠黏膜屏障功能的相关性研究[J]．临床和实验医学杂志，2019,18(14):1528-1531.

[18] LIU JQ. Understanding the structural shifts of gut microbiota in patients with chronic viral hepatitis B[D]. Shanghai:Shanghai Jiao Tong University,2011.(in Chinese)刘嘉颀．慢性乙型肝炎患者肠道菌群结构的分子生态学研究[D]．上海:上海交通大学，2011.

[19] TONG XB. Clinical analysis of 90 cases of cirrhotic ascites with spontaneous bacterial peritonitis[J]. Int Med China,2015,10(5):672-673.(in Chinese)童锡宝．肝硬化腹水伴自发性细菌性腹膜炎90例临床分析[J]．内科，2015,10(5):672-673.

[20] YI AF. Essentials of hepatitis B cirrhosis complicated with spontaneous bacterial peritonitis[J]. J Qiqihar Med Coll,2014,35(6):844-845.(in Chinese)易爱芬．乙肝肝硬化并发自发性细菌性腹膜炎关键要点探索[J]．齐齐哈尔医学院学报，2014,35(6):844-845.

[21] WEI CJ,LI DH,WANG CM. Corynebacterium urealyticum-an important pathogen of clinical opportunistic infections[J]. Int J Lab Med,2017,38(1):89-91.(in Chinese)魏超君，李德红，王超美．解脲棒杆菌———重要的临床机会性感染病原菌[J]．国际检验医学杂志，2017,38(1):89-91.

Relative Articles

[1]	Jinyuan TANG, Chenfenglin YANG, Dongle LIANG, Yuhao LUO. Role of exosomes in intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 181-186. doi: 10.12449/JCH240130
[2]	Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
[3]	Yang MAN, Zhiyi LIN, Zhang MIAO, Lerong YAN, Xiao CHENG, Renyi JING, Rong BAI, Pingwen HUANG, Hongwei ZHANG, Xinyu PENG. Comorbidity of hepatic cystic echinococcosis with HBV/HCV infection, liver cirrhosis, and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(3): 601-605. doi: 10.3969/j.issn.1001-5256.2022.03.020
[4]	Ziwei GUO, Hening CHEN, Xu CAO, Jiaxin ZHANG, Ningyi ZHANG, Qian JIN, Xiaoke LI, Yongan YE. Mechanism of action of exosomes in the development and progression of hepatitis B virus-related chronic hepatitis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2022.09.034
[5]	Tao YAO, Zhihong XU, Jiyou YAO, Yu XIA, Minqiang LU, Tian LAN, Bing LIU. Effect of hepatocellular carcinoma cell-derived exosomes on M2 polarization of tumor-associated macrophages[J]. Journal of Clinical Hepatology, 2022, 38(3): 558-562. doi: 10.3969/j.issn.1001-5256.2022.03.013
[6]	Yehao LUO, Donghan XU, Ting LYU, Tiejian ZHAO, Lei WANG. Role and potential clinical value of exosomes in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(3): 693-697. doi: 10.3969/j.issn.1001-5256.2022.03.041
[7]	Nannan QIAN, Lulu TANG, Taohua WEI, Yue YANG, Wenjie HAO, Wenming YANG. Role and mechanism of exosome non-coding RNA in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2429-2434. doi: 10.3969/j.issn.1001-5256.2021.10.036
[8]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[9]	Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
[10]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[11]	Yao YunTing, Zhou YuanZhong, Liu Jun. Role of exosomes in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2333-2339. doi: 10.3969/j.issn.1001-5256.2020.10.038
[12]	Wang ZhiXin, Gou Ping, Yu WenHao, Ren Li, Yang DanCaiRang, Wang HaiJiu, Fan HaiNing. Measurement and bioinformatics analysis of exosomes microRNAs in bile of hepatic alveolar echinococcosis patients with biliary tract invasion[J]. Journal of Clinical Hepatology, 2020, 36(9): 2045-2049. doi: 10.3969/j.issn.1001-5256.2020.09.027
[13]	Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
[14]	Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
[15]	Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
[16]	Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
[17]	Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
[18]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[19]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[20]	Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	程玉鑫，刘亮，董适毓，李胜超，张萌. 外泌体蛋白、mRNA及非编码RNA调节肝癌发生和发展的研究进展. 实用医学杂志. 2024(06): 748-755 .
2.	王玲，曹信宇，商伟芳，丁秀婷. 慢性乙型肝炎患者外泌体miR-335-5p与肝硬化严重程度的相关性. 中国热带医学. 2024(03): 326-332 .
3.	窦金萍，高维崧，韦双，高新桃，李轶女. 外泌体MicroRNA在抗病毒免疫中的功能分析. 生物技术通报. 2024(05): 48-57 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1320) PDF downloads(259)

Establishment of a predictive model of death within 30 days for patients with liver cirrhosis and bacterial ascites

DOI: 10.3969/j.issn.1001-5256.2019.11.017